The S100A8/A9 complex reduces CTLA4 expression by immature myeloid cells Implications for pancreatic cancer-driven immunosuppression

OncoImmunology

Volumn 2, Issue 6, 2013, Pages

  Basso, Daniela ^a   Fogar, Paola ^a   Plebani, Mario ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

CD8+ T cells; CTLA4; Dendritic cells; Myeloid derived suppressive cells; Pancreatic ductal adenocarcinoma; PDL1; S100 proteins

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CD14 ANTIGEN; CD33 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; SMAD4 PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FUNCTION; CELL SURFACE; COMPLEX FORMATION; DISEASE ASSOCIATION; DOWN REGULATION; HUMAN; IMMUNE DEFICIENCY; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN SECRETION;

EID: 84886944084     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24441     Document Type: Article

References (10)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-17; PMID:20427809; http://dx.doi. org/10.1056/NEJMra0901557
3. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18:4266-76; PMID:22896693; http://dx.doi.org/10.1158/1078-0432.CCR-11-3114
4. Basso D, Fogar P, Falconi M, Fadi E, Sperti C, Frasson C, et al. Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study. PLoS One 2013; 8:e54824; PMID:23359812; http://dx.doi. org/10.1371/journal.pone.0054824
5. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
6. de la Fuente H, Cibrián D, Sánchez-Madrid F. Immunoregulatory molecules are master regulators of inflammation during the immune response. FEBS Lett 2012; 586:2897-905; PMID:22819828; http://dx.doi. org/10.1016/j.febslet.2012.07.032
7. Drake CG. Combination immunotherapy approaches. Ann Oncol 2012; 23(Suppl 8):viii41-6; PMID:22918927; http://dx.doi.org/10.1093/annonc/mds262
8. Basso D, Greco E, Padoan A, Fogar P, Scorzeto M, Fadi E, et al. Altered intracellular calcium fluxes in pancreatic cancer induced diabetes mellitus: Relevance of the S100A8 N-terminal peptide (NT-S100A8). J Cell Physiol 2011; 226:456-68; PMID:20717964; http://dx.doi.org/10.1002/jcp.22355
9. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29:2035-43; PMID:18689872; http://dx.doi.org/10.1093/carcin/bgn188
10. Vernon PJ, Loux TJ, Schapiro NE, Kang R, Muthuswamy R, Kalinski P, et al. The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloidderived suppressor cells. J Immunol 2013; 190:1372-9; PMID:23269246; http://dx.doi.org/10.4049/jimmunol. 1201151